CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in March

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 3,320,000 shares, a decrease of 5.9% from the March 15th total of 3,530,000 shares. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is currently 3.8 days.

CytomX Therapeutics Trading Down 5.4 %

Shares of CytomX Therapeutics stock opened at $1.76 on Thursday. The firm has a market capitalization of $119.20 million, a PE ratio of -87.96 and a beta of 1.00. CytomX Therapeutics has a twelve month low of $1.04 and a twelve month high of $2.86. The firm’s 50-day moving average price is $2.03 and its 200 day moving average price is $1.62.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The company had revenue of $26.61 million for the quarter, compared to analysts’ expectations of $23.36 million. On average, sell-side analysts predict that CytomX Therapeutics will post -0.21 EPS for the current fiscal year.

Insider Transactions at CytomX Therapeutics

In related news, CEO Sean A. Mccarthy sold 20,223 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total value of $42,266.07. Following the transaction, the chief executive officer now directly owns 524,481 shares of the company’s stock, valued at approximately $1,096,165.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 35,024 shares of company stock valued at $73,200 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTMX. Vanguard Group Inc. lifted its stake in CytomX Therapeutics by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 5,222,886 shares of the biotechnology company’s stock worth $13,945,000 after purchasing an additional 114,895 shares in the last quarter. BlackRock Inc. lifted its stake in CytomX Therapeutics by 0.6% in the 1st quarter. BlackRock Inc. now owns 4,992,094 shares of the biotechnology company’s stock worth $13,328,000 after purchasing an additional 29,732 shares in the last quarter. Renaissance Technologies LLC lifted its stake in CytomX Therapeutics by 24.2% in the 3rd quarter. Renaissance Technologies LLC now owns 1,805,600 shares of the biotechnology company’s stock worth $2,618,000 after purchasing an additional 351,339 shares in the last quarter. Millennium Management LLC lifted its stake in CytomX Therapeutics by 223.0% in the 4th quarter. Millennium Management LLC now owns 1,719,811 shares of the biotechnology company’s stock worth $2,752,000 after purchasing an additional 1,187,298 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in CytomX Therapeutics by 22.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,094,318 shares of the biotechnology company’s stock worth $1,587,000 after purchasing an additional 197,869 shares in the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.